Locations:
Search
Global R&D efforts expanding first-line and relapse therapy options for patients
A case study on the value of access to novel therapies through clinical trials
Two thirds of patients responded to CAR T-cell therapy
On-demand stem cell mobilizer is an effective salvage strategy
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Dispelling myths and sharing practical experiences
Research indicates strong rationale for expanding trial eligibility criteria
Retrospective study yields clues to understanding risk of secondary myeloid neoplasms
Novel three-drug regimen used to manage life-threatening developments
Momelotinib, a new JAK inhibitor, inches closer to market approval
Claims data reveal disorder is often overlooked and undertreated
Advertisement
Advertisement